Comparison
While Thymosin Alpha-1 is clinically used in some countries as an immunomodulator for chronic hepatitis B/C and as an adjuvant in cancer therapy, enhancing cell-mediated immunity41487, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While Thymosin Alpha-1 works as a 28-amino-acid thymic peptide fragment of prothymosin alpha that activates dendritic cells and T cells primarily via TLR9/MyD88/NF-κB signaling, enhancing Th1 responses and NK-cell cytotoxicity414, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
Thymosin Alpha-1 is 28 amino acids long, whereas Tirzepatide is longer as it has a length of 39 amino acids. Thymosin Alpha-1 is made up of a sequence of Serine, Aspartic acid, Alanine, Alanine, Valine, Aspartic acid, Threonine, Serine, Serine, Glutamic acid, Isoleucine, Threonine, Threonine, Lysine, Aspartic acid, Leucine, Lysine, Glutamic acid, Lysine, Lysine, Glutamic acid, Valine, Valine, Glutamic acid, Glutamic acid, Alanine, Glutamic acid, Asparagine. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
Thymosin Alpha-1
PTMA
Tirzepatide
Not assigned in the current dataset.